An Introduction to the Institute for Clinical Economic Review (ICER) and Their Implications for New Sickle Cell Disease Treatments: A Primer on the Issues
|
On Jan. 16, PIPC facilitated a webinar with sickle cell stakeholders, patients, advocates, caregivers and families providing information about the metric used to assess the value of health care treatments called the quality-adjusted life year or “QALY” as well as the primary organization conducting QALY-based value assessments called the Institute for Clinical Economic Review (ICER). Because ICER will assess the value of new sickle cell disease treatments in March 2020, it is important for all stakeholders to understand QALYs, ICER and how those value assessments may be used by public and private payers in their decisions related to drug coverage and formularies.
We encourage both patients and caregivers to take and share the survey that was discussed on the webinar. Please reach out to Thayer Surette ([email protected]) if you would like to share your story on video or in an op-ed. She will work with you to make this a very light lift, and patient stories are important to this process. |
|
| voh_sickle_cell_discussion.pdf |
